Feb 28, 2022 · In Targovax, Dr. Gaal's core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and ...
Feb 28, 2022 · Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has appointed Dr. Lubor Gaal as Chief ...
28.02.2022 · In Targovax, Dr. Gaal's core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and ...
Targovax: Shareholder disclosure by Radforsk Investeringsstiftelse. Publicerad: 2021-12-05 (Cision) Onsdag 1 december. Targovax ASA - Exercise of subscription rights in the rights issue by close associate of a primary insider. Publicerad: 2021-12-01 (Cision) Tisdag 30 november.
Mar 07, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.
Jan 12, 2022 · Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that Innovation Norway has awarded Targovax an ...
Targovax strengthens focus on ONCOS oncolytic virus development program. Conference call The company will host a conference call which will include a QA session ...
Feb 15, 2022 · Largest shareholders. Latest update February 21, 2022. Data from February 15, 2022. ... renate.birkeli@targovax.com +47 922 61 624. Annual Report 2021. Released March ...
04.11.2021 · Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2021 results. Targovax's CEO ...
shareholder. Each subscription right gives the right to subscribe for one new share in Targovax. The subscription period commenced on 30 November 2021 and expires on 14 December 2021 at 16:30 CET. Following to the completion of the Rights Issue, the share capital of Targovax will be NOK 18,832,659.10 divided into 188,326,591 shares.